{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:29:50Z","timestamp":1793734190170,"version":"4.6.1"},"reference-count":104,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>The emergence of anti-vascular endothelial growth factor (anti-VEGF) therapy has marked a paradigm shift in the treatment of retinal and choroidal vascular diseases. Following the identification of VEGF as a central mediator of pathological angiogenesis and vascular permeability, anti-VEGF molecules have undergone significant evolution with increasing molecular sophistication and efficacy. Landmark clinical trials have defined contemporary treatment paradigms, along with established and emerging therapeutic indications related to anti-VEGF injections. This comprehensive review outlines the progression of anti-VEGF agents across successive generations, highlighting their mechanisms of action, pharmacokinetic and pharmacodynamic properties, and complications associated with and challenges related to anti-VEGF therapy, including the financial implications of long-term treatment in routine clinical practice. Recent advances in injection techniques, sustained drug-delivery systems, alternative delivery routes, growing availability of biosimilars, and gene-based therapies offer promising strategies to reduce treatment burden and improve cost-effectiveness. In addition to the conventional intravitreal route, alternate routes of anti-VEGF injections, like subretinal, supra-choroidal, and topical therapies, are being explored in various phases of the ongoing clinical trials. However, safety issues are vital for the clinical adaptability of the newer injection regimens, especially sustained drug deliveries and gene therapies. Furthermore, emerging technologies such as artificial intelligence-assisted home optical coherence tomography monitoring are poised to transform disease surveillance and personalized care. Collectively, these developments are expected to reshape the future landscape of anti-VEGF therapy and improve global retinal disease outcomes.<\/jats:p>","DOI":"10.4103\/ijo.ijo_3311_25","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:01:28Z","timestamp":1777478488000},"page":"767-776","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Anti-vascular endothelial growth factor therapy for posterior segment diseases: Progress, challenges, and the road ahead"],"prefix":"10.4103","volume":"74","author":[{"given":"Chitaranjan","family":"Mishra","sequence":"first","affiliation":[{"name":"Department of Vitreo-retina, Trilochan Netralaya, Sambalpur, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabatika","family":"Mohanty","sequence":"additional","affiliation":[{"name":"Department of Vitreo-retina, Sankara Eye Hospital, Hinjilicut, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somy","family":"Purohit","sequence":"additional","affiliation":[{"name":"Department of Vitreo-retina, Trilochan Netralaya, Sambalpur, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udayasree","family":"Orugonda","sequence":"additional","affiliation":[{"name":"Department of Vitreo-retina, Trilochan Netralaya, Sambalpur, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishnavi","family":"Patil","sequence":"additional","affiliation":[{"name":"Department of Vitreo-retina, Trilochan Netralaya, Sambalpur, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"R2-20261103","first-page":"729","article-title":"Retinal neovascularization","volume":"54","author":"Wise","year":"1956","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R3-20261103","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/359843a0","article-title":"Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis","volume":"359","author":"Shweiki","year":"1992","journal-title":"Nature"},{"key":"R4-20261103","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/359845a0","article-title":"Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo","volume":"359","author":"Plate","year":"1992","journal-title":"Nature"},{"key":"R5-20261103","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1016\/S2214-109X(20)30425-3","article-title":"Trends in prevalence of blindness and distance and near vision impairment over 30 years: An analysis for the Global Burden of Disease Study","volume":"9","year":"2021","journal-title":"Lancet Glob Health"},{"key":"R6-20261103","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.ophtha.2014.12.007","article-title":"Visual impairment and blindness avoided with Ranibizumab in hispanic and non-hispanic whites with diabetic macular edema in the United States","volume":"122","author":"Varma","year":"2015","journal-title":"Ophthalmology"},{"key":"R7-20261103","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1001\/jamaophthalmol.2013.7647","article-title":"The effects of technological advances on outcomes for elderly persons with exudative age-related macular degeneration","volume":"132","author":"Sloan","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R8-20261103","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ajo.2011.10.016","article-title":"Incidence of legal blindness from age-related macular degeneration in denmark: Year 2000 to 2010","volume":"153","author":"Bloch","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"R9-20261103","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s10792-024-03299-z","article-title":"Advancements and emerging trends in ophthalmic anti-VEGF therapy: A bibliometric analysis","volume":"44","author":"Deng","year":"2024","journal-title":"Int Ophthalmol"},{"key":"R10-20261103","doi-asserted-by":"crossref","first-page":"e56741","DOI":"10.2196\/56741","article-title":"Patient-centered economic burden of diabetic macular edema: Retrospective cohort study","volume":"10","author":"Choi","year":"2024","journal-title":"JMIR Public Health Surveill"},{"key":"R11-20261103","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1177\/2474126420971982","article-title":"A History of anti-VEGF inhibitors in the ophthalmic literature: A bibliographic review","volume":"5","author":"Whitescarver","year":"2021","journal-title":"J Vitreoretin Dis"},{"key":"R12-20261103","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2165\/00129784-200707060-00002","article-title":"The therapeutic potential of VEGF inhibition in diabetic microvascular complications","volume":"7","author":"Tremolada","year":"2007","journal-title":"Am J Cardiovasc Drugs Drugs Devices Interv"},{"key":"R13-20261103","first-page":"263","article-title":"Pegaptanib in the treatment of wet, age-related macular degeneration","volume":"1","author":"Vinores","year":"2006","journal-title":"Int J Nanomedicine"},{"key":"R14-20261103","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/jcpt.12146","article-title":"Ranibizumab for age-related macular degeneration: A meta-analysis of dose effects and comparison with no anti-VEGF treatment and bevacizumab","volume":"39","author":"Jiang","year":"2014","journal-title":"J Clin Pharm Ther"},{"key":"R15-20261103","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.ophtha.2005.06.007","article-title":"A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema","volume":"112","author":"Cunningham","year":"2005","journal-title":"Ophthalmology"},{"key":"R16-20261103","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3928\/15428877-20070501-09","article-title":"Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity","volume":"38","author":"Travassos","year":"2007","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"R17-20261103","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3928\/1542-8877-20050701-15","article-title":"Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion","volume":"36","author":"Rosenfeld","year":"2005","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"R18-20261103","doi-asserted-by":"crossref","first-page":"107","DOI":"10.51329\/mehdiophthal1526","article-title":"Anti-vascular endothelial growth factor therapies in ophthalmology","volume":"14","author":"Koksaldi","year":"2025","journal-title":"Med Hypothesis Discov Innov Ophthalmol J"},{"key":"R19-20261103","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: The comparison of age-related macular degeneration treatments trials","volume":"123","author":"Maguire","year":"2016","journal-title":"Ophthalmology"},{"key":"R20-20261103","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"R21-20261103","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","article-title":"Faricimab treat-and-extend for diabetic macular edema: Two-year results from the randomized phase 3 YOSEMITE and RHINE trials","volume":"131","author":"Wong","year":"2024","journal-title":"Ophthalmology"},{"key":"R22-20261103","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA and LUCERNE: Two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2","volume":"131","author":"Khanani","year":"2024","journal-title":"Ophthalmology"},{"key":"R23-20261103","first-page":"12","article-title":"Second-generation anti-VEGF agents for neovascular AMD: Newer agents have significantly altered the treatment landscape for AMD","volume":"22","author":"Walter","year":"2025","journal-title":"Retinal Physician"},{"key":"R24-20261103","first-page":"1796","article-title":"Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs","volume":"38","author":"Sharma","year":"2024","journal-title":"Eye Lond Engl"},{"key":"R26-20261103","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.2147\/DDDT.S383101","article-title":"Progress and challenges of anti-VEGF agents and their sustained-release strategies for retinal angiogenesis","volume":"16","author":"Xu","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"R27-20261103","doi-asserted-by":"crossref","first-page":"13004","DOI":"10.3390\/ijms241613004","article-title":"Twenty years of anti-vascular endothelial growth factor therapeutics in neovascular age-related macular degeneration treatment","volume":"24","author":"Moon","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R28-20261103","first-page":"1010","article-title":"Clinical pharmacology of intravitreal anti-VEGF drugs","volume":"32","author":"Fogli","year":"2018","journal-title":"Eye Lond Engl"},{"key":"R29-20261103","first-page":"CD011230","article-title":"Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration","volume":"9","author":"Moja","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R30-20261103","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"key":"R31-20261103","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.1073\/pnas.85.16.5879","article-title":"Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli","volume":"85","author":"Huston","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R32-20261103","first-page":"802","article-title":"Faricimab: Expanding horizon beyond VEGF","volume":"34","author":"Sharma","year":"2020","journal-title":"Eye Lond Engl"},{"key":"R33-20261103","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: A multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"key":"R34-20261103","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","article-title":"EVEREST study: Efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy","volume":"32","author":"Koh","year":"2012","journal-title":"Retina Phila Pa"},{"key":"R35-20261103","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.2174\/1389450122999210128180725","article-title":"Anti-VEGF therapy in myopic CNV","volume":"22","author":"Toto","year":"2021","journal-title":"Curr Drug Targets"},{"key":"R36-20261103","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10792-024-03168-9","article-title":"Efficacy of anti-VEGF intravitreal injection in traumatic submacular hemorrhage: A retrospective study","volume":"44","author":"Wang","year":"2024","journal-title":"Int Ophthalmol"},{"key":"R37-20261103","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.oret.2025.03.027","article-title":"Long-term effects of anti-VEGF therapy versus panretinal photocoagulation on retinal vessel caliber in eyes with proliferative diabetic retinopathy","volume":"9","author":"Shen","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"R38-20261103","first-page":"1140","article-title":"Intravitreal anti-vascular endothelial growth factor therapies for retinal disorders","volume":"16","author":"Hang","year":"2023","journal-title":"Pharm Basel Switz"},{"key":"R39-20261103","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/IAE.0000000000003658","article-title":"Incidence of new diabetic macular edema in fellow eyes of patients in the vista and vivid studies","volume":"43","author":"Dhoot","year":"2023","journal-title":"Retina Phila Pa"},{"key":"R40-20261103","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"key":"R41-20261103","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5005\/jp-journals-10008-1132","article-title":"Intraocular pressure rise after anti-VEGF treatment: Prevalence, possible mechanisms and correlations","volume":"7","author":"Kampougeris","year":"2013","journal-title":"J Curr Glaucoma Pract"},{"key":"R42-20261103","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/aos.15089","article-title":"Previous intravitreal injection as a risk factor of posterior capsule rupture in cataract surgery: A systematic review and meta-analysis","volume":"100","author":"Bjerager","year":"2022","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"R43-20261103","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/j.jcrs.0000000000000047","article-title":"Risk of posterior capsular rupture during phacoemulsification cataract surgery in eyes with previous intravitreal antivascular endothelial growth factor injections","volume":"46","author":"Nagar","year":"2020","journal-title":"J Cataract Refract Surg"},{"key":"R44-20261103","first-page":"8","article-title":"Retinal tears and rhegmatogenous retinal detachment after intravitreal injections: Its prevalence and case reports","volume":"21","author":"Karabag","year":"2015","journal-title":"Digit J Ophthalmol DJO"},{"key":"R45-20261103","first-page":"787","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: A review of literature","volume":"27","author":"Falavarjani","year":"2013","journal-title":"Eye Lond Engl"},{"key":"R46-20261103","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ajo.2018.11.023","article-title":"The impact of prefilled syringes on endophthalmitis following intravitreal injection of Ranibizumab","volume":"199","author":"Storey","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"R47-20261103","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.1038\/s41598-023-32874-0","article-title":"Intravitreal anti-vascular endothelial growth factor monotherapy in age-related macular degeneration with submacular hemorrhage","volume":"13","author":"Maruyama-Inoue","year":"2023","journal-title":"Sci Rep"},{"key":"R48-20261103","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1038\/s41598-018-28938-1","article-title":"Risk factors for breakthrough vitreous hemorrhage after intravitreal anti-VEGF injection in age-related macular degeneration with submacular hemorrhage","volume":"8","author":"Shin","year":"2018","journal-title":"Sci Rep"},{"key":"R49-20261103","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40942-021-00307-7","article-title":"Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: A narrative review","volume":"7","author":"Anderson","year":"2021","journal-title":"Int J Retina Vitr"},{"key":"R50-20261103","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.ophtha.2019.12.031","article-title":"Brolucizumab: Evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration","volume":"127","author":"Nguyen","year":"2020","journal-title":"Ophthalmology"},{"key":"R51-20261103","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","article-title":"Retinal vasculitis and intraocular inflammation after intravitreal injection of Brolucizumab","volume":"127","author":"Baumal","year":"2020","journal-title":"Ophthalmology"},{"key":"R52-20261103","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.4103\/IJO.IJO_2973_23","article-title":"Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group","volume":"72","author":"Agarwal","year":"2024","journal-title":"Indian J Ophthalmol"},{"key":"R53-20261103","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ajo.2015.04.013","article-title":"Endophthalmitis after intravitreal injections: Incidence, presentation, management, and visual outcome","volume":"160","author":"Dossarps","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"R54-20261103","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3928\/23258160-20140306-08","article-title":"Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents","volume":"45","author":"Fileta","year":"2014","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R55-20261103","first-page":"559","article-title":"Incidence of endophthalmitis after intravitreal injections: Risk factors, microbiology profile, and clinical outcomes","volume":"26","author":"Mishra","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"R56-20261103","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1136\/bjophthalmol-2012-302435","article-title":"Intravitreal injections at the Massachusetts eye and ear infirmary: Analysis of treatment indications and postinjection endophthalmitis rates","volume":"97","author":"Englander","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"R57-20261103","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/IAE.0b013e31820a67e4","article-title":"Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: Causative organisms and possible prevention strategies","volume":"31","author":"McCannel","year":"2011","journal-title":"Retina Phila Pa"},{"key":"R58-20261103","doi-asserted-by":"crossref","first-page":"545","DOI":"10.4103\/ijo.IJO_431_17","article-title":"Using intravitreal bevacizumab (Avastin\u00ae)-Indian scenario","volume":"65","author":"Kumar","year":"2017","journal-title":"Indian J Ophthalmol"},{"key":"R59-20261103","first-page":"25158414221090103","article-title":"Is perioperative blood pressure monitoring during intravitreal injections important?","volume":"14","author":"Debbarma","year":"2022","journal-title":"Ther Adv Ophthalmol"},{"key":"R60-20261103","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.oret.2022.06.010","article-title":"Cardiovascular and mortality risk with intravitreal vascular endothelial growth factor inhibitors in patients with diabetic retinopathy","volume":"6","author":"Roh","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"R61-20261103","first-page":"153","article-title":"Increased mortality after intravitreal injections of anti-VEGF for neovascular AMD among patients with prior stroke or acute myocardial infarction","volume":"36","author":"Chen","year":"2022","journal-title":"Eye Lond Engl"},{"key":"R62-20261103","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41433-020-0911-3","article-title":"Risk of stroke associated with intravitreal ranibizumab injections in age-related macular degeneration: A nationwide case-crossover study","volume":"35","author":"Kim","year":"2021","journal-title":"Eye"},{"key":"R63-20261103","first-page":"2073","article-title":"Evidence-based guidelines for intravitreal Anti-VEGF therapy for diabetic retinopathy in chronic kidney disease","volume":"16","author":"Sharma","year":"2025","journal-title":"Diabetes Ther Res Treat Educ Diabetes Relat Disord"},{"key":"R64-20261103","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/bjophthalmol-2020-315933","article-title":"Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: A real-world analysis of 28 658 patient eyes","volume":"105","author":"Ciulla","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"R65-20261103","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.3390\/cells10051049","article-title":"Anti-VEGF-resistant retinal diseases: A review of the latest treatment options","volume":"10","author":"Wallsh","year":"2021","journal-title":"Cells"},{"key":"R66-20261103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2025.04.032","article-title":"Sustained suppression of VEGF for treatment of retinal and choroidal vascular diseases","volume":"277","author":"Campochiaro","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"R67-20261103","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","article-title":"Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration","volume":"99","author":"Holz","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"R68-20261103","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ophtha.2017.10.010","article-title":"Real-world vision in age-related macular degeneration patients treated with single anti-VEGF drug type for 1 year in the IRIS registry","volume":"125","author":"Rao","year":"2018","journal-title":"Ophthalmology"},{"key":"R69-20261103","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.oret.2019.05.017","article-title":"Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: A real-world analysis of 49 485 eyes","volume":"4","author":"Ciulla","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"R70-20261103","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jcjo.2024.05.007","article-title":"Subretinal hyperreflective material in regions of atrophy and fibrosis in eyes with neovascular age-related macular degeneration","volume":"60","author":"Lindenberg","year":"2025","journal-title":"Can J Ophthalmol J Can Ophtalmol"},{"key":"R71-20261103","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1167\/iovs.66.1.47","article-title":"The landscape of vascular endothelial growth factor inhibition in retinal diseases","volume":"66","author":"Lin","year":"2025","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R72-20261103","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1097\/IAE.0b013e318240a516","article-title":"Causes of unsuccessful ranibizumab treatment in exudative age-related macular degeneration in clinical settings","volume":"32","author":"Cohen","year":"2012","journal-title":"Retina Phila Pa"},{"key":"R73-20261103","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1136\/bjo-2024-326124","article-title":"Anti-VEGF injections and macular atrophy progression in patients with neovascular age-related macular degeneration in remission","volume":"109","author":"Mehta","year":"2025","journal-title":"Br J Ophthalmol"},{"key":"R74-20261103","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1172\/JCI129862","article-title":"Anti-VEGF therapy: Higher potency and long-lasting antagonism are not necessarily better","volume":"129","author":"Usui-Ouchi","year":"2019","journal-title":"J Clin Invest"},{"key":"R75-20261103","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1172\/JCI65157","article-title":"Targeted deletion of Vegfa in adult mice induces vision loss","volume":"122","author":"Kurihara","year":"2012","journal-title":"J Clin Invest"},{"key":"R76-20261103","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.oret.2019.09.016","article-title":"Type 1 choroidal neovascularization is associated with reduced localized progression of atrophy in age-related macular degeneration","volume":"4","author":"Pfau","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"R77-20261103","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1167\/iovs.63.11.4","article-title":"The Fovea-protective impact of double-layer sign in eyes with foveal-sparing geographic atrophy and age-related macular degeneration","volume":"63","author":"Fukuyama","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R78-20261103","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1167\/iovs.64.5.28","article-title":"Mechanisms of acquired resistance to Anti-VEGF therapy for neovascular eye diseases","volume":"64","author":"Sharma","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R79-20261103","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1167\/iovs.15-16686","article-title":"Systemic counterregulatory response of placental growth factor levels to intravitreal aflibercept therapy","volume":"56","author":"Zehetner","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R80-20261103","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1167\/iovs.16-20922","article-title":"HTRA1 and TGF-\u03b21 concentrations in the aqueous humor of patients with neovascular age-related macular degeneration","volume":"58","author":"Tosi","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R81-20261103","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.oret.2017.04.004","article-title":"Bevacizumab injection in patients with neovascular age-related macular degeneration increases angiogenic biomarkers","volume":"2","author":"Cabral","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"R82-20261103","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1089\/jop.2020.0038","article-title":"Changes in aqueous cytokine levels following intravitreal aflibercept in treatment-naive patients with diabetic macular edema","volume":"36","author":"Juncal","year":"2020","journal-title":"J Ocul Pharmacol Ther"},{"key":"R83-20261103","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ophtha.2023.09.018","article-title":"Ophthalmology workforce projections in the United States, 2020 to 2035","volume":"131","author":"Berkowitz","year":"2024","journal-title":"Ophthalmology"},{"key":"R84-20261103","first-page":"1072","article-title":"Gene therapy for wet age-related macular degeneration","volume":"12","author":"Barthelemy","year":"2025","journal-title":"Bioeng Basel Switz"},{"key":"R85-20261103","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/jamaophthalmol.2024.4401","article-title":"Economic burden of late-stage age-related macular degeneration in Bulgaria, Germany, and the US","volume":"142","author":"Paudel","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"R86-20261103","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.oret.2017.12.006","article-title":"Medicare spending on anti-vascular endothelial growth factor medications","volume":"2","author":"Patel","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"R87-20261103","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.2147\/OPTH.S384995","article-title":"Time and distance cost of longer acting anti-VEGF therapies for macular degeneration: Contributions to drug cost comparisons","volume":"16","author":"Meer","year":"2022","journal-title":"Clin Ophthalmol Auckl NZ"},{"key":"R88-20261103","first-page":"1260","article-title":"Clinical and economic burden of neovascular age-related macular degeneration by disease status: A US claims-based analysis","volume":"27","author":"Almony","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"R89-20261103","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s40123-025-01104-3","article-title":"Clinical and socioeconomic burden of retinal diseases: Can biosimilars add value? A narrative review","volume":"14","author":"Hariprasad","year":"2025","journal-title":"Ophthalmol Ther"},{"key":"R90-20261103","doi-asserted-by":"crossref","first-page":"666","DOI":"10.4103\/ijo.IJO_1538_20","article-title":"The economic burden of diabetic retinopathy care at a tertiary eye care center in South India","volume":"69","author":"Orji","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"R91-20261103","first-page":"3392","article-title":"Anti-VEGF biosimilars for retinal diseases survey 2023- India (Bio-INDAS) by the International Retina Biosimilar Study Group (Inter-BIOS Group) in collaboration with the Vitreo-Retinal Society of India (VRSI)","volume":"38","author":"Sharma","year":"2024","journal-title":"Eye Lond Engl"},{"key":"R92-20261103","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/IAE.0b013e31822c296b","article-title":"Bilateral same-day intravitreal injections using a single vial and molecular bacterial screening for safety surveillance","volume":"32","author":"Woo","year":"2012","journal-title":"Retina Phila Pa"},{"key":"R93-20261103","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ajo.2023.07.012","article-title":"KESTREL and KITE phase 3 studies: 100-week results with brolucizumab in patients with diabetic macular edema","volume":"260","author":"Wykoff","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"R94-20261103","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.2147\/DDDT.S427416","article-title":"Faricimab: Transforming the future of macular diseases treatment-A comprehensive review of clinical studies","volume":"17","author":"Panos","year":"2023","journal-title":"Drug Des Devel Ther"},{"key":"R95-20261103","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaophthalmol.2023.2421","article-title":"Effect of high-dose intravitreal Aflibercept, 8 mg, in patients with neovascular age-related macular degeneration: The phase 2 CANDELA randomized clinical trial","volume":"141","author":"Wykoff","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"R96-20261103","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1001\/jamaophthalmol.2022.2495","article-title":"Ranibizumab injection (Susvimo) implant septum dislodgement in a patient with neovascular age-related macular degeneration","volume":"140","author":"Timmons","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"R97-20261103","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ajo.2024.11.009","article-title":"Refillable drug reservoirs for retinal vascular diseases","volume":"277","author":"Clark","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"R98-20261103","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"R99-20261103","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"R100-20261103","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat Rev Genet"},{"key":"R101-20261103","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cytogfr.2025.06.005","article-title":"Neuroprotective properties of ciliary neurotrophic factor in the retina for the treatment of macular telangiectasia type 2","volume":"84","author":"Nystuen","year":"2025","journal-title":"Cytokine Growth Factor Rev"},{"key":"R102-20261103","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ajo.2024.12.010","article-title":"Suprachoroidal delivery of viral and nonviral vectors for treatment of retinal and choroidal vascular diseases","volume":"277","author":"Lim","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"R103-20261103","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ajo.2024.12.002","article-title":"Subretinal gene therapy for treatment of retinal and choroidal vascular diseases","volume":"277","author":"Khanani","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"R104-20261103","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ajo.2025.03.016","article-title":"Can sustained suppression of VEGF be achieved by topical ocular delivery?","volume":"277","author":"Bingaman","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"R105-20261103","first-page":"3209","article-title":"New targets in diabetic retinopathy: Addressing limitations of current treatments through the Sema3A\/Nrp1 pathway","volume":"39","author":"Sivaprasad","year":"2025","journal-title":"Eye Lond Engl"},{"key":"R106-20261103","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ajo.2024.10.031","article-title":"Home optical coherence tomography and sustained delivery approaches: A perfect marriage","volume":"277","author":"Holekamp","year":"2025","journal-title":"Am J Ophthalmol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3311_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:00:25Z","timestamp":1793732425000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_3311_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":104,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_3311_25","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"2025-12-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-31","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}